YIH
GLUE icon

Y-Intercept (HK)’s Monte Rosa Therapeutics GLUE Stock Holding History

Y-Intercept (HK)’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$609K Buy
+25,149
New +$475K 0.01% 1252

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Y-Intercept (HK)'s GLUE Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 25,149 shares worth $609K. The stake represents 0.01% of the portfolio and ranks #1252 among its holdings.

193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Y-Intercept (HK) held 25,149 shares of Monte Rosa Therapeutics worth $609K as of Q2 2026.
  • Monte Rosa Therapeutics was a new Y-Intercept (HK) position in Q2 2026.
  • Monte Rosa Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1252 holding.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.